Vitrolife AB (publ) (STO:VITR)
Sweden · Delayed Price · Currency is SEK | Market Cap | 14.14B -32.9% |
| Revenue (ttm) | 3.41B -5.7% |
| Net Income | -5.01B |
| EPS | -37.01 |
| Shares Out | 135.42M |
| PE Ratio | n/a |
| Forward PE | 20.66 |
| Dividend | 1.10 (1.03%) |
| Ex-Dividend Date | May 6, 2026 |
| Volume | 183,061 |
| Average Volume | 173,625 |
| Open | 107.30 |
| Previous Close | 106.80 |
| Day's Range | 104.40 - 107.30 |
| 52-Week Range | 84.60 - 160.70 |
| Beta | 1.72 |
| RSI | 47.45 |
| Earnings Date | Jul 16, 2026 |
About Vitrolife AB
Vitrolife AB (publ) provides assisted reproduction products in Europe, the Middle East, Africa, Asia-Pacific, and the Americas. It offers sperm processing, oocyte retrieval needles, micromanipulation pipettes, time-lapse systems, and evaluation tools, laser and imaging systems, IVF media and oil, embryo transfer, cryopreservation, and genomics kits. The company also provides eWitness and Labware products, such as dishes, pipettes, tubes, and VitroTemp. The company was incorporated in 1989 and is based in Gothenburg, Sweden. [Read more]
Financial Performance
Financial StatementsNews
Report from the Annual General Meeting of Vitrolife AB (publ)
The Annual General Meeting of Vitrolife AB (publ) was held today on Tuesday 5 May 2026. The Annual General Meeting resolved in accordance with all proposals presented by the Board and the Nomination C...
Vitrolife AB (VTRLY) Q1 2026 Earnings Call Highlights: Strong North American Growth Amid Middle ...
Vitrolife AB (VTRLY) Q1 2026 Earnings Call Highlights: Strong North American Growth Amid Middle East Challenges
Vitrolife AB Earnings Call Transcript: Q1 2026
Organic growth reached 5% in local currencies, with strong North America and APAC performance offsetting Middle East declines. Gross margin hit 59.9%, and EBITDA margin was 31.1%. Innovation and restructuring are expected to further support profitability.
Vitrolife AB Quarterly report: Q1 2026
Vitrolife AB has published its Q1 2026 quarterly earnings report on April 23, 2026.
Vitrolife AB Slides: Q1 2026
Vitrolife AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 23, 2026.
Vitrolife AB Earnings Call Transcript: Q1 2026
Organic growth reached 5% in local currencies, with strong North America and APAC performance offsetting Middle East declines. Gross margin hit 59.9%, and EBITDA margin was 31.1%. Innovation and restructuring are expected to further support profitability.
Vitrolife AB Quarterly report: Q1 2026
Vitrolife AB has published its Q1 2026 quarterly earnings report on April 23, 2026.
Vitrolife AB Slides: Q1 2026
Vitrolife AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 23, 2026.
Vitrolife AB Earnings Call Transcript: Q1 2026
Organic growth reached 5% in local currencies, with strong North America and APAC performance offsetting Middle East declines. Gross margin hit 59.9%, and EBITDA margin was 31.1%. Innovation and restructuring are expected to further support profitability.
Vitrolife AB Quarterly report: Q1 2026
Vitrolife AB has published its Q1 2026 quarterly earnings report on April 23, 2026.
Vitrolife AB Slides: Q1 2026
Vitrolife AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 23, 2026.
Vitrolife AB (publ) - Interim report Q1, 2026: Strong growth in Consumables and Technologies
GOTHENBURG, Sweden, April 23, 2026 /PRNewswire/ -- First quarter Sales of SEK 807 (842) million, an increase of 5% in local currencies and 4% decrease in SEK. Sales per region, in local currencies,...
Notice of the Annual General Meeting of Vitrolife AB (publ)
GOTHENBURG, Sweden, April 1, 2026 /PRNewswire/ -- The Annual General Meeting of Vitrolife AB (publ), 556354-3452, will be held on Tuesday 5 May 2026 at 17:00 CEST at Elite Park Avenue Hotel, Kungsport...
Vitrolife AB Earnings Call Transcript: Q4 2025
Q4 saw 6% organic growth (excl. discontinued business), with strong Americas and APAC performance, but margins declined due to currency and mix effects. Strategic restructuring in Genetic Services and investments in sales, marketing, and IT aim to drive profitable growth as market conditions normalize in 2026.
Vitrolife AB Annual report: Q4 2025
Vitrolife AB has published its Q4 2025 annual report on February 3, 2026.
Vitrolife AB Quarterly report: Q4 2025
Vitrolife AB has published its Q4 2025 quarterly earnings report on February 3, 2026.
Vitrolife AB Slides: Q4 2025
Vitrolife AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 3, 2026.
Vitrolife AB Earnings Call Transcript: Q4 2025
Q4 saw 6% organic growth (excl. discontinued business), with strong Americas and APAC performance, but margins declined due to currency and mix effects. Strategic restructuring in Genetic Services and investments in sales, marketing, and IT aim to drive profitable growth as market conditions normalize in 2026.
Vitrolife AB Annual report: Q4 2025
Vitrolife AB has published its Q4 2025 annual report on February 3, 2026.
Vitrolife AB Quarterly report: Q4 2025
Vitrolife AB has published its Q4 2025 quarterly earnings report on February 3, 2026.
Vitrolife AB Slides: Q4 2025
Vitrolife AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 3, 2026.
Vitrolife AB Earnings Call Transcript: Q4 2025
Q4 saw 6% organic growth (excl. discontinued business), with strong Americas and APAC performance, but margins declined due to currency and mix effects. Strategic restructuring in Genetic Services and investments in sales, marketing, and IT aim to drive profitable growth as market conditions normalize in 2026.
Vitrolife AB Annual report: Q4 2025
Vitrolife AB has published its Q4 2025 annual report on February 3, 2026.
Vitrolife AB Quarterly report: Q4 2025
Vitrolife AB has published its Q4 2025 quarterly earnings report on February 3, 2026.
Vitrolife AB Slides: Q4 2025
Vitrolife AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 3, 2026.